Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinismGlobeNewsWire • 10/08/24
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutideGlobeNewsWire • 10/08/24
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18thGlobeNewsWire • 09/13/24
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee WarrantsGlobeNewsWire • 09/12/24
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutideGlobeNewsWire • 09/09/24
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewsWire • 08/30/24
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its PortfolioThe Motley Fool • 07/05/24
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billionGlobeNewsWire • 06/25/24
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billionGlobeNewsWire • 06/25/24
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billionGlobeNewsWire • 06/25/24
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintideGlobeNewsWire • 06/20/24
Zealand Pharma announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosisGlobeNewsWire • 06/07/24
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASLGlobeNewsWire • 06/06/24
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines AgencyGlobeNewsWire • 05/31/24
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024GlobeNewsWire • 05/29/24
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutideGlobeNewsWire • 05/23/24